NTLA vs AUPH โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AUPH Captures Institutional Edge (3โ1 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aurinia Pharmaceuticals Inc (AUPH) driven by superior Valuation, Growth & Margin, Options & Structure while NTLA counters with relative strength in Momentum & Technical. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus AUPH at 13.6x Forward P/E and 51.6% operating margin (+13.9% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against AUPH sits in CONSOLIDATION (48th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NTLA Revenue | AUPH Revenue | NTLA Op. Margin | AUPH Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | $0M | -298.6% | -11930.9% | NTLA |
| FY2019 | $40M | $0M | -246.8% | -28598.4% | NTLA |
| FY2020 | $60M | $50M | -235.5% | -208.1% | AUPH |
| FY2021 | $30M | $50M | -810.4% | -396.3% | AUPH |
| FY2022 | $50M | $130M | -879.0% | -83.2% | AUPH |
| FY2023 | $40M | $180M | -1420.5% | -52.2% | AUPH |
| FY2024 | $60M | $240M | -923.1% | -2.0% | AUPH |
| FY2025 | $70M | $280M | -651.7% | 37.1% | AUPH |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NTLA | AUPH | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.5B | $2.1B | Larger Scale | AUPH |
| Trailing P/E Ratio Valuation | N/M | 7.0x | Lower Multiple | AUPH |
| Forward P/E Ratio Valuation | N/M | 13.6x | Lower Multiple | AUPH |
| Revenue Growth (YoY) Growth | -48.0% | +13.9% | Higher Growth | AUPH |
| Operating Margin (TTM) Profitability | -826.0% | 51.6% | Higher Margin | AUPH |
| Net Profit Margin Profitability | 0.0% | 97.7% | Higher Margin | AUPH |
| Return on Equity (ROE) Capital Efficiency | -62.6% | 61.4% | Higher ROE | AUPH |
| 52-Week Range Position Momentum | 20% ($8โ$18) | 34% ($14โ$19) | Stronger Trend | AUPH |
| Beta / 30D Volatility Risk Regime | 2.30ฮฒ ยท 87% Vol | 0.67ฮฒ ยท 36% Vol | Lower Realized Risk | AUPH |
| Unified Institutional Score Composite Signal | 49.9 / 100 (HOLD) | 55.7 / 100 (HOLD) | Higher Composite | AUPH |